SKP 0141
Alternative Names: SKP-0141Latest Information Update: 18 Mar 2025
At a glance
- Originator SK Pharma
- Class Antihaemorrhagics; Blood coagulation factors
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 18 Dec 2024 Preclinical trials in Haemophilia A (Prevention) in South Korea (unspecified route) before December 2024 (SK Pharma pipeline, December 2024)
- 18 Dec 2024 Preclinical trials in Haemophilia A in South Korea (unspecified route), before December 2024 (SK Pharma pipeline, December 2024)
- 18 Dec 2024 SK Plasma plans phase I/III trial in Hemophilia A (In children, In adolescents, In adults, In elderly and Treatment experienced) in March 2025 (Injection) (NCT06738901)